Metformin inhibits lung cancer cells proliferation through repressing microRNA-222 |
| |
Authors: | Yuqi Wang Weimin Dai Xiangyang Chu Bo Yang Ming Zhao Yu’e Sun |
| |
Institution: | 1. Department of Thoracic Surgery, General Hospital of the People’s Liberation Army, Beijing, 100853, China
|
| |
Abstract: | Metformin, which is commonly used as an oral anti-hyperglycemic agent of the biguanide family, may reduce cancer risk and improve prognosis. However, the mechanism by which metformin affects various cancers, including lung cancer, remains unknown. MiR-222 induces cell growth and cell cycle progression via direct targeting of p27, p57 and PTEN in cancer cells. In the present study, we used A549 and NCI-H358 human lung cancer cell lines to study the effects and mechanisms of metformin. Metformin treatment reduced expression of miR-222 in these cells (p < 0.05). As a result, protein abundance of p27, p57 and PTEN were increased in cells exposed to metformin. Therefore, these data provide novel evidence for a mechanism that may contribute to the anti-neoplastic effects of metformin suggested by recent population studies and justifying further work to explore potential roles for it in lung cancer treatment. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|